A Phase 4 interventional study of Trimethoprim-Sulfamethoxazole (TMP-SMX) and Usual Care in Kidney Transplant, Urinary Tract Infection(UTI) and Antibiotic Prophylaxis, sponsored by University of California, San Francisco. Not yet recruiting at 1 site in United States. Open to participants aged 12 Years to 29 Years. Per ClinicalTrials.gov, last updated 2026-09-11.
Sponsored by University of California, San Francisco · Phase 4, Interventional, and Prevention
Among 271 studies in Urinary Tract Infections with a site in United States — 44 open to participants now, 54 under way, 2 of them phase 3. Urinary Tract Infections · United States.
Among the 271 studies in Urinary Tract Infections with a site in United States, this one is the 147th largest by planned enrollment of the 222 interventional ones that give a count, is one of 2 that started in 2028, is one of 38 in phase 4, reaches primary completion later than 53 of the 53 other live ones, and was the 250th registered.
803 studies on the registry are indexed under Urinary Tract Infections; 133 are open to participants now.
Browse Urinary Tract Infections studies →44 of the 271 studies in Urinary Tract Infections with a site in United States are open now. Recruiting first, the newest first:
University of Miami · Sites in United States
Ages 18+ · Women only
GlaxoSmithKline · Sites in United States
Ages 18–50 · Women only · Healthy volunteers
Megan Bradley · Sites in United States
Ages 65+ · Women only
Baylor College of Medicine · Sites in United States
Ages 0 mo–5 mo · Men only
Ohio University · Sites in United States
Ages 18+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 84 Urinary Tract Infections studies recruiting now, 50 (60%) set no upper age limit and 23 (27%) stop at 75 or younger; 15 take children under 18; 17 take healthy volunteers.
This study: 12 Years to 29 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
271 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 27 · Phase 2 41 · Phase 3 33 · Phase 4 38
First in 1988; this study’s year is marked. 2 started in 2028.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50 is below the median of 131 across 560 interventional studies indexed under Urinary Tract Infections.
Median enrollment 100 across the 222 interventional studies, 200 across the 49 observational. Of the 189 that completed or were terminated, 88 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
71 of 271 have an industry lead sponsor. The 10 most frequent:
University of California, San Francisco is the lead sponsor of 2,169 studies on the registry; 372 are open to participants now.
Of its 267 completed or terminated interventional studies of FDA-regulated products, 202 (76%) have results posted.
University of California, San Francisco has 6 studies filed under Urinary Tract Infections — fewer than ten, so there is no comparison to draw.
25 of the studies in Urinary Tract Infections with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07686055Phase 3Megan BradleyPrecision Management of Urinary Tract Symptoms in Older Women | 2027-02-01 |
| NCT06976125University Hospitals Cleveland Medical CenterApplication of a Prediction Model for Directing Antibiotic Use in the Treatment of Urinary Tract Infection in an Ambulatory Setting | 2026-12-01 |
| NCT07453693Bonafide HealthAn Efficacy Study of a Dietary Supplement Drink Mix for Urinary Health Improvement | 2026-12-15 |
| NCT07542834Ohio UniversityUsing Virtual Reality to Improve Medical Training | 2026-12-31 |
| NCT05723601Wake Forest University Health SciencesPreference of Women With Recurrent Urinary Tract Infection for Vaginal Estradiol Tablet vs Cream | 2027-01 |
Among the 271 studies in Urinary Tract Infections with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to learn if a common antibiotic called trimethoprim-sulfamethoxazole (TMP-SMX) can help prevent urinary tract infections (UTIs) in children and young adults who recently had a kidney transplant. Most people take TMP-SMX for about 6 months after getting a kidney transplant. In this study, researchers want to see what happens if people keep taking it for 6 more months.
The main questions this study is asking are:
Researchers will compare TMP-SMX to a placebo (a look-alike pill that does not contain any medication) to see if TMP-SMX works to prevent UTIs.
Participants will:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TMP-SMX
Drug: Trimethoprim-Sulfamethoxazole (TMP-SMX)
Placebo
Other: Usual Care
Kidney transplant recipients will continue to take TMP-SMX daily from months 6-12 after transplant
Participants will take a placebo from months 6-12 after transplant and continue to receive all standard usual care related to their kidney transplant status
Agreement Between Participant Self-Report and Medical Records on Clinical Events (Measured by Cohen's Kappa)
The investigators will look at how closely participants' self-reports of events (urinary tract and associated infections, acute kidney injury events, and hospitalizations) match what is identified through their electronic health records. To do this, the investigators will use a statistical tool called Cohen's kappa, which shows how much agreement there is between the two sources.
Time frame: From enrollment to the end of the study drug period (6 months)
Number of Participants Who Enroll After Screening
The investigators will track how many people decide to join and how many people decline to join the study after completing the screening process.
Time frame: Baseline/Study Day 1 (i.e., date that informed consent is signed for those who choose to participate)
Medication Adherence Assessed by Self-Report
The investigators will ask participants how often they are taking the pills as directed, through monthly surveys and at all study visits.
Time frame: From enrollment to the end of the study drug period (6 months)
Trial Retention
The investigators will keep track of how many participants complete the last study visit
Time frame: From enrollment to the end of the study drug period (6 months)
Event Rate of All-Cause Hospitalizations by Treatment Arm
The investigators will keep track of when participants are hospitalized, using feedback from participants themselves (for the first 6 months) as well as data from their electronic medical records (for 6 additional months, for a total of 12 months). Event rates will be used to compare outcomes between the treatment (TMP-SMX continuation) and placebo arms.
Time frame: From enrollment through the end of the study period (12 months)
Urinary Tract Infections by Treatment Arm
The investigators will keep track of when participants report having a urinary tract infection, using feedback from participants themselves (for the first 6 months) as well as data from their electronic medical records (for 6 additional months, for a total of 12 months). Event rates will be used to compare outcomes between the treatment (TMP-SMX continuation) and placebo arms.
Time frame: From enrollment to the end of the study period (12 months)
Acute Kidney Injury Events by Treatment Arm
The investigators will keep track of when participants report having acute kidney injury events, using feedback from participants themselves (for the first 6 months) as well as data from their electronic medical records (for 6 additional months, for a total of 12 months). Event rates will be used to compare outcomes between the treatment (TMP-SMX continuation) and placebo arms.
Time frame: From enrollment to the end of the study period (12 months)
Adverse Events by Treatment Arm
The investigators will keep track of when participants report side effects and adverse events, using feedback from participants themselves as well as data from their electronic medical records
Time frame: From enrollment to the end of the study drug period (6 months)
Plan to share: No — Due to ethical considerations, the access, distribution, and reuse of the resulting scientific data will not be permitted. The study involves minors and a sample size that may be prone to "small cells" (using the Centers for Medicare and Medicaid definition of \<10 individuals with certain characteristics). We will not share individual-participant level data.
No publications or documents are linked to this record.
Start is estimated for Oct 2028; primary completion for Dec 2031, 38 months later.
Of 44 non-industry phase 4 interventional studies under Urinary Tract Infections, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 50. This study's planned 38 months is close to that.
Counting every sponsor, half of 50 studies reached it within 37 months; a quarter within 22 and three quarters within 46.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of California, San Francisco →